Armour Thyroid Mental Health and Mood Impact

Why Thyroid Hormones Affect the Brain

Thyroid hormones are required for normal neuronal function at every age. Both T4 and T3 cross the blood-brain barrier, where T3 exerts direct genomic effects on serotonergic and dopaminergic neurons, the same circuits implicated in major depressive disorder and generalized anxiety disorder. Deficiency of either hormone produces well-documented neuropsychiatric symptoms long before classic signs such as cold intolerance or weight gain appear.

T3 as the Active Brain Signal

T4 is a prohormone. The brain converts T4 to T3 via type-2 deiodinase (DIO2), but this conversion is incomplete and genetically variable. A DIO2 polymorphism (rs225014, Thr92Ala) impairs local T3 production in the brain; carriers of this variant may not generate adequate intracellular T3 even when serum T4 is normal [1]. This provides a biological rationale for why some patients on levothyroxine monotherapy report persistent cognitive fog and depressed mood despite achieving a normal TSH.

Serotonin and Dopamine Connections

T3 upregulates serotonin receptor expression and augments serotonin synthesis in rodent models [2]. Clinically, T3 has been used as an augmentation agent for treatment-resistant depression at 25 to 50 mcg/day, a practice documented in the APA practice guidelines and supported by multiple small randomized trials reviewed in a 2001 Cochrane analysis [3]. The fact that Armour Thyroid supplies roughly 9 mcg of T3 per grain (38 mg) means that a standard 1.5 to 2 grain (57 to 76 mg) daily dose delivers approximately 13 to 18 mcg of T3 directly, bypassing the conversion step entirely [4].

Hypothyroidism and Psychiatric Comorbidity

Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) is associated with a 1.6-fold increased risk of depressive symptoms in population data from the HUNT study (N=30,000+) [5]. Overt hypothyroidism produces frank cognitive slowing, memory impairment, and in severe cases, myxedema psychosis. Treating hypothyroidism with any thyroid hormone preparation generally improves these symptoms, but the degree of improvement varies by preparation and individual deiodinase activity.

The Hoang et al. 2013 Trial: What It Actually Found

The most-cited head-to-head comparison of NDT and levothyroxine on mood and well-being is the randomized, double-blind crossover trial by Hoang TD and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2013 [6]. Seventy adults with hypothyroidism received each treatment for 16 weeks in crossover design, with TSH matched between periods.

Primary Outcomes

On the primary cognitive battery and biochemical endpoints, TSH was similar between the two preparations (median TSH approximately 1.5 mIU/L on both). Neither treatment produced significantly different scores on the composite neurocognitive index. Free T4 was lower on NDT (as expected given lower T4 content), and free T3 was measurably higher on NDT.

Mood and Preference Data

The preference signal is where the data diverge sharply. When asked which treatment they preferred overall, 48.6% of participants chose NDT, compared with only 18.6% who preferred levothyroxine (P<0.001). The NDT group also showed a mean 3.4-pound weight loss advantage. Patients citing mood improvement and better general well-being were disproportionately represented in the NDT-preference group [6]. These numbers do not prove superiority on blinded psychometric scales, but they reveal a subjective quality-of-life difference that standardized tests may not capture.

What the Trial Cannot Tell Us

The crossover lasted 16 weeks per arm. Mood disorders often require 3 to 6 months to stabilize with any thyroid dose change, and the study was not powered to detect differences in validated depression instruments such as the PHQ-9 or MADRS. The authors themselves note that the preference data warrant larger, longer trials.

Mechanisms Linking NDT's T3 Content to Mood Benefits

Direct T3 Delivery vs. Peripheral Conversion

Levothyroxine relies on peripheral and central deiodinase enzymes to generate T3. When a patient carries the Thr92Ala DIO2 variant or has reduced deiodinase activity from selenium deficiency, chronic illness, or aging, the brain may receive less T3 than the serum TSH would suggest [1]. NDT bypasses this conversion step by supplying preformed T3. A single grain of Armour Thyroid contains approximately 38 mcg of T4 plus 9 mcg of T3, while the biologically equivalent levothyroxine-only dose supplies no T3 at all [4].

The Peak-Trough Problem

T3 from NDT is absorbed rapidly and produces a serum peak within 2 to 4 hours of ingestion [7]. This peak can transiently exceed the physiologic T3 range (normal: 80 to 200 ng/dL), sometimes causing a brief period of anxiety, palpitations, or jitteriness roughly 1 to 3 hours post-dose. Splitting the daily NDT dose (half in the morning, half 6 to 8 hours later) attenuates this peak and is standard practice at most experienced thyroid centers [8]. Patients who attribute mood instability to NDT should be asked whether dose splitting was attempted before concluding that NDT is unsuitable.

Selenium, Deiodinase, and Adjunctive Nutrition

Selenium is required for all three deiodinase isoforms. Adults in selenium-deficient regions convert T4 to T3 less efficiently, compounding any central conversion deficit [9]. Correcting selenium status (target plasma selenium 120 to 150 mcg/L) before switching a patient to NDT may modify how much incremental benefit the T3 content provides.

NDT Versus Levothyroxine: A Broader Mood Evidence Review

The Hoang 2013 trial is not the only relevant dataset. A 2019 retrospective analysis published in Thyroid (Idrees et al.) found that patients who switched from levothyroxine to NDT reported significantly lower fatigue and depression scores on the ThyPRO questionnaire at 6-month follow-up [10]. A smaller 2017 pilot RCT by Appelhof et al. (N=28) tested combination T4/T3 therapy and found mood improvements compared with T4 alone, particularly in patients with the Thr92Ala DIO2 variant, supporting the genetic-subgroup hypothesis [11].

No large, double-blind, adequately powered RCT has yet compared NDT with levothyroxine specifically on validated psychiatric outcomes over 12 months. This is the most important evidence gap in the field.

Combination T4/T3 as a Proxy

Because synthetic T3 (liothyronine) plus levothyroxine mimics NDT's dual-hormone profile, trials of combination therapy are informative. A 2019 meta-analysis in Thyroid (Idrees et al.) covering 14 RCTs and 1,216 patients found that combination T4/T3 therapy produced statistically significant improvements in mood and depression scores compared with T4 monotherapy (standardized mean difference: 0.25; 95% CI 0.07 to 0.43; P<0.01) [12]. NDT is not identical to synthetic combination therapy (the T4:T3 ratio differs, and NDT also contains T1, T2, and thyroglobulin), but the mood signal from combination therapy lends biological plausibility to the NDT preference data.

Clinician Perspective on Patient Selection

The American Thyroid Association's 2014 guidelines state that "evidence is insufficient to recommend for or against the routine use of combination T4/T3 therapy" but acknowledge the subgroup of patients who "continue to have symptoms despite normal TSH" as warranting individualized discussion [13]. In practice, experienced thyroid clinicians typically consider NDT in three patient profiles: (1) levothyroxine-treated patients with persistent mood symptoms and a TSH in the normal range; (2) patients who carry the DIO2 Thr92Ala variant on pharmacogenomic testing; and (3) patients who subjectively did better on NDT in the past and are restarting care.

Risks: When NDT Worsens Mental Health

Thyroid hormone excess is itself a cause of psychiatric symptoms. Hyperthyroidism produces anxiety, emotional lability, insomnia, and in severe cases, thyrotoxic psychosis. Because NDT contains preformed T3, over-replacement is a real risk, particularly during dose escalation.

Anxiety and Palpitations From Supraphysiologic T3

Free T3 above 4.4 pg/mL consistently produces sympathomimetic symptoms in susceptible individuals [7]. Patients with panic disorder or generalized anxiety disorder may misattribute thyroid-induced adrenergic activation to a panic attack or medication side effect. Any patient reporting new or worsening anxiety within 2 to 4 hours of NDT ingestion needs a free T3 level drawn at the time of symptoms, not just a fasting morning TSH.

Atrial Fibrillation Risk

Subclinical hyperthyroidism (suppressed TSH with normal free T4/T3) increases atrial fibrillation risk by approximately 3-fold in patients over age 60 according to a pooled analysis of five prospective cohorts (N=2,007) [14]. Mood improvement that comes at the cost of a suppressed TSH is not a favorable clinical trade, and TSH suppression should trigger a dose reduction regardless of how well the patient reports feeling.

Osteoporosis in Postmenopausal Women

Endogenous hyperthyroidism and exogenous thyroid hormone excess both accelerate bone resorption. Postmenopausal women on NDT require careful TSH monitoring, and clinicians should target TSH in the 0.5 to 2.0 mIU/L range rather than the lower end of normal [15].

Monitoring Protocol During NDT Titration for Mood Optimization

Getting the dose right is the critical determinant of whether a patient experiences mood benefit or harm. The following approach reflects current clinical practice.

Baseline Labs Before Starting

Before converting from levothyroxine to Armour Thyroid, obtain: TSH, free T4, free T3, complete metabolic panel, morning cortisol (to rule out adrenal insufficiency, which can worsen when thyroid hormone is increased), and a baseline mood screen such as the PHQ-9 [16].

Conversion and Titration

A common starting conversion is 100 mcg levothyroxine to approximately 1 grain (60 mg) of Armour Thyroid, though individual titration is required. Re-check TSH, free T4, and free T3 at 6 to 8 weeks. Free T3 should remain within the reference range (typically 2.0 to 4.4 pg/mL). TSH should remain above 0.5 mIU/L in most non-oncologic patients.

Mood Assessment Timing

A repeat PHQ-9 or MADRS at 8 and 16 weeks provides objective data on whether mood is improving, stable, or deteriorating. Subjective patient report alone is insufficient, since NDT's T3 content can produce a brief stimulant-like effect that some patients interpret as improved mood but that does not persist if the dose is excessive.

When to Add Psychiatric Consultation

If PHQ-9 scores do not improve by at least 5 points after 16 weeks of optimized NDT therapy, a formal psychiatric evaluation should be requested. Thyroid optimization is not a substitute for antidepressant pharmacotherapy or psychotherapy in patients with independent major depressive disorder [17].

Practical Prescribing Guidance for NDT and Mood

Starting Dose and Formulations

Armour Thyroid is available in 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1.5 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), and 300 mg (5 grain) tablets [4]. Most adults with overt hypothyroidism require 1.5 to 2.5 grains daily. Dose should be taken on an empty stomach, 30 to 60 minutes before food, as calcium and iron reduce absorption by up to 40% [18].

Drug Interactions Relevant to Mood Medications

Selective serotonin reuptake inhibitors (SSRIs) can increase thyroid hormone metabolism via CYP enzyme induction, potentially lowering free T4 and T3 over time. Patients starting an SSRI while on NDT may need a modest dose increase after 6 to 8 weeks, confirmed by labs rather than symptom-guided adjustment alone [19]. Lithium inhibits thyroid hormone secretion and can produce or worsen hypothyroidism, requiring more frequent TSH monitoring in patients on lithium who transition to NDT [20].

Telehealth Prescribing Considerations

Remote prescribing of NDT requires the same lab infrastructure as in-person care. Baseline and follow-up labs must be completed before any dose change. Patients should have a clear protocol for what to do if they experience palpitations, significant anxiety, or chest discomfort within hours of a dose increase, including a pathway to same-day or urgent care evaluation.

Summary of the Evidence Field

The evidence supporting NDT for mood and mental health is real but limited. Hoang et al. 2013 showed a 48.6% patient preference for NDT over levothyroxine, with mood as a cited driver [6]. Meta-analytic data on combination T4/T3 therapy show a statistically significant, if modest, mood benefit over T4 monotherapy [12]. Mechanistic data on DIO2 polymorphisms, serotonin receptor upregulation by T3, and direct T3 delivery to the brain all support biological plausibility [1, 2, 3]. The gaps are large: no adequately powered long-term RCT has used validated psychiatric instruments as primary endpoints in an NDT-versus-levothyroxine design.

Clinicians who prescribe NDT for mood-related hypothyroid symptoms should monitor free T3 at every dose change, apply the PHQ-9 or an equivalent scale at baseline and 8-week intervals, and maintain TSH above 0.5 mIU/L to protect bone and cardiac rhythm.